Codexis Inc
Closed
SectorHealthcare
2.65
Overview
Share price change
24h
Min
2.6
Max
2.88
Income | 29M 9.6M |
|---|---|
Sales | 30M 39M |
Profit margin | 24.672 |
Employees | 146 |
EBITDA | 33M 17M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +154.18% upside |
Next Earnings | 7 maj 2026 |
|---|
Market Cap | 115M 228M |
|---|---|
Previous open | 2.65 |
Previous close | 2.65 |
Technical Score
By Trading Central
Confidence
Bullish Evidence
Codexis Inc Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Codexis Inc Forecast
Price Target
By TipRanks
154.18% upside
12 Months Forecast
Average 6.38 USD 154.18%
High 11 USD
Low 2 USD
Based on 5 Wall Street analysts offering 12 month price targets forCodexis Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Codexis Inc
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, the company is currently developing its proprietary ECO Synthesis(tm) manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
